Sawai Group Holdings Co., Ltd. (TYO:4887)

Market Cap	268.50B +18.5%
Revenue (ttm)	200.68B +9.1%
Net Income	8.23B -67.9%
EPS	70.88 -57.0%
Shares Out	115.49M
PE Ratio	27.78
Forward PE	14.34
Dividend	56.00 (2.41%)
Ex-Dividend Date	Mar 30, 2026

Volume	517,900
Average Volume	362,515
Open	2,292.50
Previous Close	2,278.50
Day's Range	2,282.50 - 2,329.50
52-Week Range	1,650.00 - 2,447.00
Beta	0.01
RSI	59.56
Earnings Date	May 15, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 3,310
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4887

Financial Performance

In fiscal year 2025, Sawai Group Holdings's revenue was 189.02 billion, an increase of 6.88% compared to the previous year's 176.86 billion. Earnings were 11.97 billion, a decrease of -12.60%.